BMS partners with drug accelerator to launch biotech

Bristol-Myers Squibb (BMS) and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BMS to acquire Forbius in oncology expansion

27 August 2020 Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.

Americas

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

Americas

BMS pays $1.85bn for immuno-oncology programme

15 February 2018 Bristol-Myers Squibb has agreed to pay $1.85 billion for an immuno-oncology programme.

More on this story

Americas

BMS to acquire Forbius in oncology expansion

27 August 2020 Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.

Americas

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

Americas

BMS pays $1.85bn for immuno-oncology programme

15 February 2018 Bristol-Myers Squibb has agreed to pay $1.85 billion for an immuno-oncology programme.

More on this story

Americas

BMS to acquire Forbius in oncology expansion

27 August 2020 Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.

Americas

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

Americas

BMS pays $1.85bn for immuno-oncology programme

15 February 2018 Bristol-Myers Squibb has agreed to pay $1.85 billion for an immuno-oncology programme.